BMJ Case Reports · 2018 · 15 citations · 30 references
Ethambutol (EMB) and isoniazid (INH) are the first-line antituberculosis (anti-TB) drugs. However, their neurotoxicity could cause adverse effect and the patients with end-stage renal disease are especially vulnerable due to the reduction in renal drug clearance. Here, we report a 36-year-old man receiving peritoneal dialysis developed progressive paralysis in lower extremities, vision loss and hoarseness 4 months after anti-TB treatment with INH, EMB and rifapentine because of concomitant pulmonary tuberculosis. A diagnosis of EMB/INH-induced peripheral neuropathy, retrobulbar neuritis and laryngoparalysis was made. The patient’s neuropathy gradually improved 2 years after discontinuation of EMB/INH. Since EMB and INH may cause simultaneously severe and complex multineuropathy in dialysis patients, their adverse effects should be closely supervised in dialysis patients.
30
Payam Nahid, Susan E. Dorman, Narges Alipanah et al. · Clinical Infectious Diseases · 2016 · 1.4K citations · Full text
Tuberculosis Treatment, Tuberculosis Prevention, Pediatric Lung Disease +21
John B. Bass, Laurence S. Farer, Philip C. Hopewell et al. · American Journal of Respiratory and Critical Care Medicine · 1994 · 1.2K citations
Susceptibility Studies, Tuberculosis Prevention, Pharmacotherapy +18
Public Health · 1923 · 460 citations
Pulmonary Tuberculosis, Antibiotics, Tuberculosis Prevention +7